News coverage about Concord Medical Services (NYSE:CCM) has trended somewhat positive on Saturday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Concord Medical Services earned a news impact score of 0.13 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.1928971702208 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of CCM stock traded down $0.13 during trading on Friday, hitting $3.00. 1,645 shares of the stock were exchanged, compared to its average volume of 4,901. Concord Medical Services has a 12 month low of $2.46 and a 12 month high of $4.83. The company has a quick ratio of 1.59, a current ratio of 1.60 and a debt-to-equity ratio of 0.20.
Separately, Zacks Investment Research downgraded shares of Concord Medical Services from a “buy” rating to a “hold” rating in a report on Thursday.
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, CyberKnife robotic radiosurgery system, proton beam therapy systems, and diagnostic imaging services.
Receive News & Ratings for Concord Medical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concord Medical Services and related companies with MarketBeat.com's FREE daily email newsletter.